$LIVN (LivaNova PLC)

$LIVN {{ '2016-07-06T15:30:53+0000' | timeago}} • Announcement

$LIVN said it is implementing organizational re-design that, in addition to existing corporate support functions, will include a Chief Operating Officer (COO). In addition, Michel Darnaud, President of Cardiac Surgery, will assist in transition of Stefano Di Lullo retirement and will be retiring in 1Q of next year.

$NUVA {{ '2017-07-28T17:40:21+0000' | timeago}} • Announcement

Jason Hannon, President and COO of $NUVA, has stepped down and Matt Link, President of US Commercial, was promoted as EVP, Strategy and Corporate Development. Skip Kiil, EVP, International is the new EVP, Global Commercial. Steve Rozow, VP, Global Operations, becomes EVP. CFO Quentin Blackford’s resignation was accepted, effective Aug 25, 2017.

$ABT {{ '2017-07-25T15:58:08+0000' | timeago}} • Announcement

$ABT has announced that the first patient has been enrolled in a clinical study evaluating the short-term use of common blood thinning medicines, called dual antiplatelet therapy (DAPT), after receiving a Xience everolimus-eluting coronary stent to unblock coronary arteries. Approx 2,000 patients at 100 sites in the US and Asia will be studied.

$BIIB {{ '2017-07-25T14:47:25+0000' | timeago}} • Announcement

$BIIB, which competes with $ABT and $PFE, posted record 2Q17 revenue, on strong Spinraza demand in the US, though YoY profit fell 18% on higher expenses. Net earnings attributable to Biogen plunged to $862.8MM, while diluted EPS fell 15.03% to $4.07. Revenue, however, jumped 6% to $3.1Bil. $BIIB lifted its outlook due to strong Spinraza sales.

$ABT {{ '2017-07-20T19:55:45+0000' | timeago}} • Webcast

For 3Q17, $ABT expects adjusted EPS of $0.64-0.66, with operational sales growth expected in the mid-single digits. At current exchange rates, the company expects operational sales growth to have a negative YoY impact of around 0.5%.

$ABT {{ '2017-07-20T19:45:56+0000' | timeago}} • Webcast

$ABT said that on a comparable operational basis, 3Q17 Established Pharmaceuticals sales growth is expected in the high double-digit, while in Nutrition, sales growth is expected in low single-digit. In Diagnostics, $ABT expects sales to increase mid-to-high single digits and in Medical Devices, sales is expected to increase double-digits.

$ABT {{ '2017-07-20T17:49:19+0000' | timeago}} • Announcement

$ABT raised its full year profit forecast backed by the intention of closing the Alere acquisition in 2017. The company raised its FY17 adjusted earnings from continuing operations guidance by $0.03 to a range of $2.43-2.53 per share. Reported EPS forecast was also raised from the range of $0.92-1.02 to $1.03-1.13, reflecting double-digit growth.

$ABT {{ '2017-07-20T17:36:53+0000' | timeago}} • Announcement

Declining operating earnings and rising costs and expenses hit $ABT 2Q17 earnings as much as 54%. Earnings plunged to $283MM or $0.15 from $615MM or $0.40 per share a year earlier. Sales, however, surged 24.4% on St. Jude Medical acquisition. On an adjusted basis, $ABT reported EPS above its previous guidance range at $0.62 per share.

$ABT {{ '2017-07-20T12:52:57+0000' | timeago}} • Infographic

$ABT Abbott Laboratories Earnings AlphaGraphic: Q2 2017 Highlights

$GS {{ '2017-07-19T11:22:37+0000' | timeago}} • Webcast

$GS advised a number of important transactions that were announced during 2Q17, including $BCR's $24Bil sale to $BDX. $AMZN's $13.7Bil acquisition of $WFM, and $DFT's $7.6Bil merger with $DLR.

$ABT {{ '2017-07-17T12:36:21+0000' | timeago}} • Announcement

$ABT is commencing a tender offer to purchase for cash all outstanding shares of Series B Convertible Perpetual Preferred Stock of Alere Inc. at a price of $402 per share of Preferred Stock. The offer will expire at 11:59 pm, NYC time, on Aug 11, 2017. There is no financing condition to the offer.

$ABT {{ '2017-07-13T12:23:21+0000' | timeago}} • Announcement

$ABT and Bigfoot Biomedical agreed to develop and commercialize diabetes management systems, integrating $ABT's FreeStyle Libre glucose sensing technology with Bigfoot's insulin delivery solutions in the United States. $ABT will provide Bigfoot with the next generation of its FreeStyle Libre glucose sensing technology.

$LIVN {{ '2017-07-12T12:45:32+0000' | timeago}} • Announcement

$LIVN appointed Keyna Skeffington as SVP and General Counsel. Skeffington most recently served as Vice President of Legal – Corporate and Securities, Deputy General Counsel and Assistant Secretary at $MDT.

$MDT {{ '2017-07-10T15:43:07+0000' | timeago}} • Announcement

$MDT announced the expanded FDA approval of the self-expanding CoreValve Evolut transcatheter aortic valve replacement platform to include patients with symptomatic severe aortic stenosis who are at an intermediate risk for open-heart surgery.

$MASI {{ '2017-06-30T12:41:36+0000' | timeago}} • Announcement

Medical technology firm $MASI entered into a partnership with Midmark Corp. for enhancing the accuracy and efficiency of vital signs acquisition in the clinical space. Under the deal, Masimo’s SET pulse oximetry technology is an available option with Midmark's IQvitals Zone. The combination provides accurate and real-time vital signs information.

$ABT {{ '2017-06-29T17:53:11+0000' | timeago}} • Announcement

$ABT announced the Health Canada license of its FreeStyle Libre Flash Glucose Monitoring System, a glucose sensing technology for adults with diabetes. This system eliminates the need for routine finger sticks or finger stick calibration, and reads glucose levels through a sensor that can be worn on the back of the upper arm for up to 14 days.

$LIVN {{ '2017-06-29T15:56:55+0000' | timeago}} • Announcement

$LIVN received FDA approval of its VNS Therapy system in patients as young as four years of age with partial onset seizures that are refractory to antiepileptic medications.

$MDT {{ '2017-06-23T12:04:14+0000' | timeago}} • Announcement

$MDT has announced a 7% increase in its quarterly cash dividend, raising the amount to $0.46 per ordinary share. The dividend is payable on July 26, 2017, to shareholders of record as of July 7, 2017.

$HAE {{ '2017-06-23T10:51:04+0000' | timeago}} • Announcement

$HAE announced the formation of a Scientific Advisory Council as part of its broader innovation agenda, advancing its commitment to science and clinical excellence. The SAC will also, as appropriate, provide opinion on strategic issues impacting product and clinical matters.

$LIVN {{ '2017-06-21T14:06:24+0000' | timeago}} • Announcement

$LIVN said its latest VNS Therapy systems received FDA approval for expanded MRI labeling, affirming VNS Therapy as the only epilepsy device approved by the FDA for MRI scans. This ensures VNS patients with latest technology may visit any MRI center in US and have access to more than 90% of scans routinely performed on patients with epilepsy.

$MDT {{ '2017-06-20T13:54:51+0000' | timeago}} • Announcement

$MDT said data from a recent study showed that its cardiac resynchronization therapy devices reduced healthcare system costs and improved therapy delivery in heart failure patients. A European health-economic analysis indicated that Medtronic’s AdaptivCRT extended life expectancy of patients by about four months, while lowering healthcare costs.

Recent Transcripts

NUVA (NuVasive, Inc.)
Thursday, July 27 2017 - 8:30pm
CRY (CryoLife Inc.)
Tuesday, July 25 2017 - 12:00pm
ABT (Abbott Laboratories)
Thursday, July 20 2017 - 1:00pm
MDT (Medtronic plc)
Thursday, May 25 2017 - 12:00pm
HAE (Haemonetics Corporation)
Monday, May 8 2017 - 12:00pm
OFIX (Orthofix International N.V.)
Thursday, May 4 2017 - 8:30pm
EXTN (Exterran Corporation)
Thursday, May 4 2017 - 3:00pm
MASI (Masimo Corporation)
Wednesday, May 3 2017 - 8:30pm
WMGI (Wright Medical Group N.V.)
Wednesday, May 3 2017 - 8:30pm
LIVN (LivaNova PLC)
Wednesday, May 3 2017 - 1:00pm
RTIX (RTI Surgical Inc.)
Thursday, April 27 2017 - 12:30pm
CRY (CryoLife Inc.)
Thursday, April 27 2017 - 12:00pm
NUVA (NuVasive, Inc.)
Tuesday, April 25 2017 - 8:30pm
ABT (Abbott Laboratories)
Wednesday, April 19 2017 - 1:00pm
EXTN (Exterran Corporation)
Thursday, March 9 2017 - 4:00pm
LIVN (LivaNova PLC)
Wednesday, March 1 2017 - 2:00pm
DLNG.PRA (Dynagas LNG Partners LP)
Tuesday, February 28 2017 - 3:00pm
OFIX (Orthofix International N.V.)
Monday, February 27 2017 - 9:30pm
VER.PRF (VEREIT, Inc.)
Thursday, February 23 2017 - 3:00pm
RTIX (RTI Surgical Inc.)
Thursday, February 23 2017 - 1:30pm

AlphaGraphics you may like